Objectives: To compare age-associated 8-year changes in total testosterone, calculated bioavailable testosterone and sex hormone binding globulin (SHBG) across five groups of men stratified according to change in body mass index (BMI) (i.e., BMI stable (70.69 kg/m 2 ), decreased (À0.7 kg/m 2 ), increased minimally (0.7-1.74 kg/m 2 ), increased moderately (1.75-3.19 kg/m 2 ) and increased most (X3.20 kg/m 2 )). Design: Eight-year longitudinal cohort study. Subjects: Four hundred and seventy-four black and 695 white men, aged 24-31 years at the time of the first hormone measurement. Measurements: Aging-related changes in serum SHBG, total testosterone and bioavailable testosterone. Results: SHBG significantly increased with age for men whose BMI decreased, and there were progressively smaller increases for men whose BMI was stable, or whose BMI increased minimally or moderately (range 1.1-0.3 nM per year, Pp0.03, respectively). There was no age relationship with SHBG among men whose BMI increased most. Total testosterone did not change with age for men whose BMI decreased, was stable or increased minimally, but for men whose BMI increased moderately and most there was a graded decrease in total testosterone with age (b ¼ À0.2 and À0.4 nM per year, respectively, Pp0.005). However, bioavailable testosterone decreased with age to a similar extent across all groups. Conclusions: These results suggest that changes in BMI during young adulthood modulate age-related changes in SHBG and total testosterone, but not bioavailable testosterone.
Introduction
Results of cross-sectional and longitudinal epidemiologic studies suggest that circulating total testosterone levels decrease as part of the normal male aging process. [1] [2] [3] [4] [5] [6] [7] Additionally, there is an age-related increase in sex hormone binding globulin (SHBG), which binds about 44% of testosterone with high affinity. The non-SHBG-bound fraction of testosterone, the bioavailable testosterone fraction, appears to decrease with age. 3, 4, 6, 7 There is evidence that decreased Leydig cell number and secretory function appears to contribute to the decline in serum testosterone. 8 However,
Harman et al. 6 suggested that changes in potentially modifiable lifestyle factors associated with aging also might play an important role in this decline.
There is evidence that the increasing level of obesity, a major public health epidemic in the United States, 9 is associated with lower levels of total testosterone and SHBG. 2, 5, 7, [10] [11] [12] [13] [14] [15] Because total testosterone decreases and SHBG increases with age, it is possible that the age-related decline in total testosterone and/or bioavailable testosterone might differ among men whose body mass index (BMI) remains stable, decreases or increases as they age. If the amount of weight change differentially affects the relationship of age with hormone and SHBG levels in men, then efforts at preventing or reducing weight gain could have important implications for the use of testosterone replacement therapy. As noted in a recent report from the Institutes of Medicine, 16 understanding the factors that contribute to low testosterone levels in men is of particular concern because a growing number of middle-and older-aged men are turning to testosterone therapy to ameliorate health conditions associated with low testosterone levels 17 despite important gaps in the scientific evidence defining its potential benefits or risks. The Coronary Artery Risk Development in Young Adults (CARDIA) Male Hormone Study (CMHS) is a longitudinal study of young adult black and white men. This study provides a unique opportunity for disentangling the associations of changes in age and BMI with changes in serum hormone levels. Using data from the CMHS, we compared the age-associated change in serum total testosterone, SHBG and bioavailable testosterone across five groups of men stratified according to their 8-year change in BMI. The focus on young to middle-aged men is of considerable interest because this might be a critical time for promoting healthy behaviors, which could impact long-term androgen exposure.
Methods

The CMHS
The CARDIA Study is a multi-center, longitudinal study designed to examine physiologic, psychological and lifestyle factors that might affect the development of cardiovascular disease risk factors in young black and white men and women. Briefly, 5115 participants who were aged 18-30 years completed a baseline examination in 1985-1986 at one of the four clinical centers: Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota or Oakland, California. Four follow-up examinations were completed in 1987-1988 (year 2), 1990-1991 (year 5), 1992-1993 (year 7) and 1995-1996 (year 10). A detailed description of the design, recruitment and methods of this study was published previously. 18 The number of black and white men who completed the baseline examination was 1157 and 1171, respectively. For the CMHS, hormone concentrations were measured in serum collected at the years 2, 7 (when available) and 10 examinations. Because the primary goal of this study was to evaluate 8-year longitudinal changes in serum hormone levels, only men who had serum available from at least years 2 and 10 examinations were included, that is, 624 blacks and 796 whites. Among these 1420 men, 1211 had serum available from the year 7 examination. We excluded two black men because their baseline age was more than 31 years. In a previous publication of data from the CMHS, 5 we showed that for both blacks and whites, total testosterone was higher in men aged 22-23 years compared to men 20-21 years old, whereas after age 24, testosterone concentrations appeared to decrease. Because of this reversal in the relationship of age with total testosterone concentration for younger compared to older men, we have excluded the 139 blacks and 101 whites who were aged 20-23 years from all analyses. In addition, we excluded nine black men with missing year 2 or 10 BMI data. The final sample size for this analysis consists of 474 blacks and 695 whites who were aged 24 years and older. The CMHS has been approved by the Institutional Review Board at Northwestern University.
Data collection
In the CARDIA Study, all data collection technicians were centrally trained and certified. The CARDIA Coordinating Center and the CARDIA Quality Control Committee monitored data collection throughout the study. Informed consent was obtained from each participant at each examination. Participants were asked to fast for 12 h before each examination. Weight and height were measured using a balance beam scale and a vertical ruler, carpenter's square or stadiometer, with participants wearing light clothing and no shoes. Height was recorded to the nearest 0.5 cm and weight to the nearest 0.5 lb. BMI was calculated as the weight (kg) divided by the height squared (m 2 ). Waist circumference was measured in duplicate at the minimum abdominal girth. Age, race and years of education were self-reported. Other self-reported information included use of prescription medication. A subset of medications might influence levels of steroid hormones or steroid-binding proteins, and/or interfere with steroid hormone binding. Therefore, medications were classified into two categories: (1) regulation or interference with binding known or likely and (2) unlikely/possible.
At each of the three examinations, blood was collected by venipuncture between 0730 and 1200 hours from over 95% of the CMHS participants. Aliquots of serum were stored at À701C within 90 min of the blood draw. Samples were packed in dry ice and shipped to a long-term freezer storage facility. The samples used in this study had not been thawed previously.
Hormone measurements
Total testosterone was measured directly using radioimmunoassay kits and SHBG was measured by chemiluminescent enzyme immunometric assay using Immulite (Diagnostic Products Corporation, Los Angeles, CA, USA). All samples for each individual were assayed in the same batch. Assay variability was monitored by including 10% of blind quality control samples in each batch of samples analyzed. The quality control serum was obtained from a large pool that was aliquoted into storage vials and labeled identical to BMI changes affect age-related changes in sex hormones SM Gapstur et al CARDIA participant samples. The intra-and inter-batch technical errors were 12.3 and 11.2%, respectively, for total testosterone and 7.9 and 11.2%, respectively, for SHBG. The concentrations of bioavailable testosterone were calculated according to the method of Södergard et al. 19, 20 The age-and BMI-adjusted partial correlations between time of blood draw and all hormone levels were p0.09. Thus, the relationships between time of blood draw and hormone levels were not considered further. Serum concentrations of testosterone and SHBG appeared normally distributed for both black and white men.
Statistical analysis
Participants were stratified according to their change in BMI between years 2 and 10 examinations. We defined the BMI stable group (reference group) as those men whose BMI varied by less than 0.7 kg/m 2 between years 2 and 10. A second group included men whose BMI decreased by 0.7 kg/m 2 or more (i.e., BMI loss). The remaining men, whose BMI increased over the 8-year period, were stratified into approximately equal tertiles. We defined these three groups as the BMI minimum gain, moderate gain and most gain groups. Table 1 shows the cut points for each of these groups.
In preliminary analyses, we examined the distribution of black men and white men across the five BMI change groups. We also computed the mean ages of men in each group at years 2 and 10 examinations. The years 2 and 10 age-and race-adjusted mean BMI of the stable group was compared to that of each of the other BMI changes groups using analysis of covariance (ANCOVA).
Using ANCOVA, years 2, 7 and 10 least-square mean concentrations of SHBG, total testosterone and bioavailable testosterone adjusted for age, BMI and race were computed for each BMI group. To better understand the 8-year change in serum hormones, we used generalized estimating equation (GEE) analyses 21 to compute regression coefficients for the overall average annual change in hormone adjusting for year 2 age, time-dependent BMI and race for each BMI change group. Because there were no meaningful differences between black and white men in the overall average annual change in hormone levels, we present the analyses with blacks and whites combined. The primary analysis focused on the aging-associated changes in SHBG, total testosterone and bioavailable testosterone in each of the BMI change groups. Again, there were no black-white differences in these results, so we present results only for the combined analyses. We used a GEE model that included covariates for race, year 2 BMI, secular changes (i.e., those changes not attributed to age) between years 2 and 7, as well as years 2 and 10, timedependent age and dummy variables for the four BMI change groups where the reference group is the BMI stable group, and we included the interaction between those dummy variables and time-dependent age. The b-coefficients for the interaction terms were used to determine the magnitude of difference in mean age-associated change of hormone level relative to the BMI stable group and each of the BMI change categories, and the P-value for the interaction term was used to assess the level of statistical significance for this difference. Additionally, the inclusion of a time-dependent indicator variable for medications, which were categorized as 'likely' to regulate or interfere with binding of androgens did not change the associations of hormones with race, age or measures of obesity. Therefore, results are presented without adjustment for medication use. All analyses were conducted using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). For the longitudinal analyses, PROC GENMOD was used and an exchangeable structure was specified for the within-subject correlation.
Results
The proportion of black and white men is approximately similar across the five BMI change groups, with the exception that the proportion of black men was higher in the most gain group and lower in the stable group (Table 1) . There were no differences in average age at year 2 across the BMI change groups. Over the 8-year follow-up period, the average weight change ranged from a decrease of 4.6 kg in the weight loss group to an increase of 16.6 kg in the most The mean BMI is significantly different (Po0.05) from that for the BMI stable group for years 2 and 10 examination, respectively.
BMI changes affect age-related changes in sex hormones SM Gapstur et al gain group. At year 2, mean BMI was significantly higher in the loss group and the most gain group compared to the BMI stable group. In addition, the 10th and 90th percentiles of BMI at year 2 were approximately similar for each of the BMI change groups and most men had a BMI less than 30 kg/m 2 . At year 10, mean BMI was significantly higher than the BMI stable group for each of the BMI gain groups. For men whose BMI increased the most, the 10th and 90th percentiles of BMI were in the overweight and morbidly obese categories of obesity at year 10.
The age-, BMI-and race-adjusted least-square mean concentrations for years 2, 7 and 10 SHBG, total testosterone and bioavailable testosterone concentrations, as well as the regression coefficients for the 8-year overall average annual change in these serum measurements are shown in Table 2 . There was an increase in serum SHBG concentration among men whose BMI decreased. Conversely, there was a statistically significant decrease in SHBG over the 8-year period among men whose BMI increased the most. Among men with stable or increased BMI, there was a decrease in total testosterone. However, there was no meaningful change in total testosterone among men in the BMI loss group. Bioavailable testosterone decreased significantly in all BMI change groups.
The regression coefficients for the age-associated change in SHBG, total testosterone and bioavailable testosterone, for each of the BMI change groups was compared to that for men whose BMI was stable (Table 3 and Figure 1 ). As shown in Figure 1a , serum SHBG concentration generally increased with age. This increase was greatest for men whose BMI decreased, with progressively smaller increases in men whose BMI was stable, or whose BMI increased minimally or moderately. Conversely, there was no relationship of age with SHBG among men whose BMI increased the most. Compared to the BMI stable groups, the age-related differences in the mean change in serum SHBG concentrations were statistically significant for all other BMI change groups. As shown in Figure 1b , there were no significant age-related Mean change per year increase in age is adjusted for year 2 BMI, race and terms for secular changes in hormone levels between years 2 and 7, and years 2 and 10.
BMI changes affect age-related changes in sex hormones SM Gapstur et al changes in total testosterone among men whose BMI decreased, remained stable or increased minimally. Whereas, total testosterone significantly decreased with age in the groups of men whose BMI increased moderately or the most. However, the age-related decrease in bioavailable testosterone was similar across the five BMI change groups (Figure 1c ).
Discussion
As discussed previously, Harman et al. 6 proposed that ageassociated changes in potentially modifiable lifestyle factors could contribute to the decline in serum testosterone levels in men. The scarcity of longitudinal data on changes in hormones, BMI and age in a well-characterized sample of adult men has not allowed for a detailed analysis of this hypothesis. In our cohort of young adult black and white men, we found that the relationship of age with change in serum SHBG level was modified by change in BMI such that there was a strong positive relationship between age and SHBG for men whose BMI decreased. There were also significant positive, albeit attenuated, associations between SHBG and age for the groups of men with stable BMI or minimal or moderate increases, and there was essentially no change in SHBG for the group of men whose BMI increased the most. Remarkably, we found no meaningful change in total testosterone with age among men whose BMI decreased, remained stable or increased minimally, whereas there was a graded age-associated decrease in total testosterone among men whose BMI increased moderately and the most. However, change in BMI did not modify the agerelated decline in bioavailable testosterone. Although the nature of the relationships of aging, changes in BMI and changes in sex hormones is unclear, there has been some concern that in men, an age-related decrease in testosterone could result in decreased lean body mass and increased visceral fat mass. Alternatively, it is possible that increasing BMI, which results from low-energy expenditure and high-energy intake, could result in decreased testosterone levels. Although the effects of short-term weight loss interventions on serum sex hormone levels in obese men have been examined in several studies, we are aware of no other long-term prospective observational study that examined the extent to which the age-related changes in serum hormone levels were modified by changes in BMI among normally aging men. In our analysis of young to middleaged adults, we found that the relationships of serum SHBG and total testosterone -but not bioavailable testosteronewith age were modified by the level of 8-year BMI change. Reasons for differences across BMI change groups in the associations of aging with SHBG and total testosterone, but not bioavailable testosterone, might be attributed to the androgen-mediated feedback mechanisms on the hypothalamic-pituitary-gonadal axis. A high level of obesity is associated with high serum insulin concentration. 22 In vivo insulin is inversely associated with circulating SHBG concentration 12, 23 and in vitro insulin inhibits SHBG production in hepatoma cells. 24 As a result, there might be a compensatory reduction in testosterone secretion, with no resultant effect on the bioavailable fraction. An increasing level of obesity might also lead to a decrease in total testosterone through increased peripheral conversion of androgens to estrogens by the enzyme aromatase, which is found primarily in adipose tissue. Unfortunately, the volume of serum available precluded us from measuring serum estrogens in our cohort of men. Based on our findings in young adult men, it is unclear whether the changes in total testosterone but not bioavailable testosterone with increasing obesity contribute to the signs and symptoms attributed to androgenic changes in Figure 1 (a-c) Longitudinal age associations of SHBG (a), total testosterone (b) and bioavailable testosterone (c) over an 8-year period for men whose BMI decreased (K), remained stable, (-) increased minimally (m), increased moderately (E) or most (') during the 8-year follow-up period.
BMI changes affect age-related changes in sex hormones SM Gapstur et al aging men. It is possible that obesity could have intracellular effects that might be mediated, in part through SHBG. For example, there is evidence suggesting that SHBG is able to activate the androgen receptor in the prostate, 25 and SHBG has been shown to be a strong positive predictor of bone turnover rate in young men. 26 The primary strength of the current study is the availability of high-quality anthropometric data and hormone concentrations in serially collected serum samples over 8 years, which provides a basis for examining the effects of long-term changes in BMI on changes in hormone levels. A limitation of this study is that there was only a single fasted morning blood draw from each person at each examination, which does not allow for assessment of changes in the diurnal variation of serum testosterone concentrations. This is particularly important because the diurnal variation in testosterone appears to be suppressed in older men compared to younger men. 27 Further research is warranted to understand whether there are differential effects of BMI on this variation. Additionally, small volume of serum (approximately 0.5 ml) available for this study precluded the direct measurement of bioavailable testosterone. Therefore, we used the methods of Söderberg et al. 19 to compute bioavailable testosterone concentrations, a method that has been shown to be highly sensitive and specific. 20 In summary, the results of this longitudinal study of young to middle-aged men indicate that SHBG increases with age for those whose BMI remains stable, but this increase is attenuated with increasing BMI. In addition, although there was a graded decrease in serum total testosterone among men whose BMI increased, there was no change in total testosterone with increasing age among men whose BMI decreased, remained stable or increased only minimally. These findings challenge the concept that there is a general decrease in total testosterone during young to middle-aged adulthood. However, the decrease in bioavailable testosterone with age did not differ across levels of BMI change. In conclusion, because of the lack of any difference in the age-related decline in bioavailable testosterone across the BMI change groups, it is not clear what role the gradual increase in obesity, which has become extremely common in our culture, has on the signs and symptoms attributed to low testosterone levels in aging men. Regardless, an important role for obesity cannot be excluded because SHBG might have independent intracellular effects. Moreover, because of the inverse associations of BMI with total testosterone and SHBG, our results suggest that it is important to assess bioavailable testosterone in addition to total testosterone to prevent overtreatment with androgen replacement therapy.
